1Lopez AD,Murray CC. The global burden of disease,1990-2020.Nat Med,1998,4(11) :1241-1243.
2Chaudhuri R, Livinggston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids.in chronic asthma. Am J Respir Crit Care Med, 2003,168( 11 ):1308-1311.
3Larj MJ, Bleecker ER. Therapeutic responses in asthma and COPD. Chest,2004,126(2 suppl) :138-149.
4Sin DD,Lacy P, York E,et al. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med,2004,170(7): 1164.
5Calverley PM, Pauwel RA, Vestbol, et al. Combined sameterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet, 2003,361 (9356):449-456.
6Cazzola M,Dahl R. Inhaled combination therapy with long-acting β2-agonists and corticoeteroids in stable COPD. Chest, 2004,126(1) :220-237.
7Man WDC,Mustfa N,Nikoletou D,et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax, 2004,59 (6): 471-476.
8Barnes PJ. Mechanisms in COPD: differences from asthma.Chest, 2000,117(2 suppl): 10-14.
9Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of paitents with chronic obstructive pulmonary disease: a randomized, doseranging study. Lancet,2001,358(9278) :265-270.
10MacNee W. Oxidative stress and lung inflammation in airways disease. Eur J Pharmacol,2001,429(1-3) :195-207.
